Ana M Gonzalez-Angulo

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:7098-104. 2005
  2. ncbi request reprint Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
  3. doi request reprint Earlier age of onset of BRCA mutation-related cancers in subsequent generations
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:321-5. 2012
  4. ncbi request reprint Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
    A M Gonzalez-Angulo
    Department of Breast Medical Oncology Department of Systems Biology
    Ann Oncol 25:1122-7. 2014
  5. pmc Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
    A M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Cancer Treat Rev 39:313-20. 2013
  6. pmc Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 119:7-15. 2013
  7. doi request reprint Everolimus in the treatment of hormone receptor-positive breast cancer
    Mariana Chavez-MacGregor
    The University of Texas, MD Anderson Cancer Center, Department of Breast Medical Oncology, 1155 Herman P Pressler, CPB5 3540, Houston, TX 77030, USA
    Expert Opin Investig Drugs 21:1835-43. 2012
  8. ncbi request reprint Breast cancer and metastasis: on the way toward individualized therapy
    Adriana Priscila Trapé
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, U S A
    Cancer Genomics Proteomics 9:297-310. 2012
  9. pmc A new hypothesis for the cancer mechanism
    Xiaolong Meng
    Breast Medical Oncology Department, MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Metastasis Rev 31:247-68. 2012
  10. pmc Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology, Systems Biology, Biostatistics, Surgical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1109-19. 2012

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:7098-104. 2005
    ..To identify clinicopathological factors predictive of distant metastasis in patients who had a pathologic complete response (pCR) after neoadjuvant chemotherapy (NC)...
  2. ncbi request reprint Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
    ..The purpose of this study was to review the efficacy and safety of a similar regimen outside the setting of a clinical trial...
  3. doi request reprint Earlier age of onset of BRCA mutation-related cancers in subsequent generations
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:321-5. 2012
    ..In this study, the authors assessed age at diagnosis in 2 generations of families with known mutations to investigate for earlier onset in subsequent generations...
  4. ncbi request reprint Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
    A M Gonzalez-Angulo
    Department of Breast Medical Oncology Department of Systems Biology
    Ann Oncol 25:1122-7. 2014
    ..We aim to determine pharmacodynamics changes and response of adding everolimus to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)...
  5. pmc Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
    A M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Cancer Treat Rev 39:313-20. 2013
    ..Identification of biomarkers to help select patients who are most likely to benefit from these treatments is an essential unmet need...
  6. pmc Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 119:7-15. 2013
    ....
  7. doi request reprint Everolimus in the treatment of hormone receptor-positive breast cancer
    Mariana Chavez-MacGregor
    The University of Texas, MD Anderson Cancer Center, Department of Breast Medical Oncology, 1155 Herman P Pressler, CPB5 3540, Houston, TX 77030, USA
    Expert Opin Investig Drugs 21:1835-43. 2012
    ..Everolimus , an mTOR-inhibitor has clinical activity against breast cancer and has shown to restore sensitivity to endocrine therapy...
  8. ncbi request reprint Breast cancer and metastasis: on the way toward individualized therapy
    Adriana Priscila Trapé
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, U S A
    Cancer Genomics Proteomics 9:297-310. 2012
    ..Also, we highlight the importance of re-designing clinical trials towards metastasis prevention for improvement of personalized care...
  9. pmc A new hypothesis for the cancer mechanism
    Xiaolong Meng
    Breast Medical Oncology Department, MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Metastasis Rev 31:247-68. 2012
    ..The hypothesis can be used to interpret and guide cancer prevention, recurrence, metastasis, in vitro and in vivo studies, and personalized treatments...
  10. pmc Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology, Systems Biology, Biostatistics, Surgical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1109-19. 2012
    ..We removed stroma-associated genes to minimize confounding effects. PAM50 was used to assign molecular class. Paired t test and gene set analysis were used to identify differentially expressed genes and pathways...
  11. doi request reprint Targeting the PI3K signaling pathway in cancer therapy
    Chandra Bartholomeusz
    The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology and System Biology, Houston, TX 77030, USA
    Expert Opin Ther Targets 16:121-30. 2012
    ..g., breast, bladder, prostate, thyroid, ovarian and NSCLC. Targetable genetic aberrations in this pathway give us many opportunities for development of targeted therapies for different types of cancer...
  12. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  13. doi request reprint Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Breast Cancer 8:516-21. 2008
    ....
  14. ncbi request reprint Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:396-400. 2006
    ....
  15. ncbi request reprint Trends for inflammatory breast cancer: is survival improving?
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 12:904-12. 2007
    ..Clinical trials focusing on the management of this aggressive disease are warranted. Disclosure of potential conflicts of interest is found at the end of this article...
  16. ncbi request reprint Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Ander son Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, Texas 77030, USA
    Oncologist 11:857-67. 2006
    ..Here, we review the recently completed clinical trials of adjuvant trastuzumab in the adjuvant setting. HER-2/neu testing, patient selection, cardiotoxicity, duration of therapy, and directions for future research are discussed...
  17. doi request reprint Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:2472-8. 2009
    ..To examine the androgen receptor (AR) levels in breast cancer and to assess the impact of AR expression on patient outcomes...
  18. pmc High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:5700-6. 2009
    ..To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer...
  19. pmc PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1093-101. 2011
    ..There is a high level of discordance in PTEN level, PIK3CA mutations, and receptor status between primary tumors and metastases that may influence patient selection and response to PI3K-targeted therapies...
  20. ncbi request reprint Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:1760-6. 2004
    ..D. Anderson Cancer Center (Houston, TX)...
  21. pmc Future of personalized medicine in oncology: a systems biology approach
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 28:2777-83. 2010
    ....
  22. ncbi request reprint Women age < or = 35 years with primary breast carcinoma: disease features at presentation
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2466-72. 2005
    ..The purpose of the current study was to describe a population of young patients with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival...
  23. ncbi request reprint Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1439, USA
    Clin Breast Cancer 7:326-30. 2006
    ..The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC)...
  24. pmc Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:1082-9. 2011
    ..Survival was estimated by Kaplan-Meier method and compared with log-rank. Cox proportional hazards models were fit to determine the independent association of mutation status with outcome...
  25. pmc Metformin: a therapeutic opportunity in breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1695-700. 2010
    ..These data, and the epidemiological and retrospective data supporting the antineoplastic effects of metformin, provide the rationale to study the role of metformin for breast cancer therapy in a variety of clinical settings...
  26. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  27. pmc Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  28. ncbi request reprint Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1037-44. 2006
    ..To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR)...
  29. doi request reprint Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer
    Himanshu Nagar
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 81:782-7. 2011
    ....
  30. doi request reprint Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer
    Jeffrey M Albert
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 77:1296-302. 2010
    ....
  31. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
    ....
  32. ncbi request reprint Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  33. doi request reprint Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer
    Catherine M Kelly
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 30:930-5. 2012
    ..We investigated whether capecitabine and docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) or weekly paclitaxel (WP) followed by FEC would improve relapse-free survival (RFS) in operable breast cancer...
  34. pmc Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:7381-8. 2009
    ..To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS)...
  35. doi request reprint Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  36. doi request reprint Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:932-8. 2011
    ..The goal of this study was to determine the impact of disease progression during NCT on surgical management...
  37. doi request reprint Prognostic value of initial clinical disease stage after achieving pathological complete response
    Shaheenah Dawood
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 13:6-15. 2008
    ..Overall, patients who achieved a pCR had a low rate of recurrence. However, higher clinical stage and IBC were associated with worse outcomes in breast cancer patients who achieved a pCR after PST...
  38. doi request reprint Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 1484, The University of TexasMDAnderson Cancer Center, 1400 Pressler St, Houston, TX 77030, USA
    Ann Surg 257:173-9. 2013
    ..This study was performed to evaluate long-term local-regional control rates after breast-conserving therapy (BCT) for patients undergoing surgery before or after neoadjuvant chemotherapy...
  39. doi request reprint Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
    Rachel L Theriault
    Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 11:325-31. 2011
    ..This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype...
  40. pmc Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
    Naoki Niikura
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030, USA
    J Clin Oncol 30:593-9. 2012
    ..We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors...
  41. doi request reprint Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer
    Merih Guray Durak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 17:462-9. 2011
    ..Age at diagnosis and associated FCC are significant factors in predicting recurrence in patients with T1a,bN0 IBC. Adjuvant systemic therapy should be discussed with and considered for young patients with T1a,bN0 IBC...
  42. doi request reprint Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
    Ricardo H Alvarez
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:1210-7. 2010
    ....
  43. doi request reprint Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer
    Débora de Melo Gagliato
    All authors The University of Texas MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 32:735-44. 2014
    ..We evaluated the association between TTC and survival according to breast cancer subtype and stage at diagnosis...
  44. ncbi request reprint Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy
    Sean E McGuire
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1004-9. 2007
    ..The aim of this study was to investigate the role of postmastectomy radiation therapy in women with breast cancer who achieved a pathologic complete response (pCR) to neoadjuvant chemotherapy...
  45. doi request reprint Prognostic significance of HER-2 status in women with inflammatory breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 112:1905-11. 2008
    ..The purpose of this study was to define the prognostic impact of HER-2 status on survival outcomes of patients with IBC...
  46. ncbi request reprint Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4107-15. 2006
    ..D. Anderson Cancer Center (Houston, TX)...
  47. ncbi request reprint p53 expression as a prognostic marker in inflammatory breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6215-21. 2004
    ..We retrospectively analyze the expression of p53 as a prognostic marker to predict pathological complete response and survival in patients with IBC...
  48. pmc Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology and Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:4891-8. 2008
    ..The aim of this study was to evaluate trends in and factors affecting survival in a large population-based cohort of patients with newly diagnosed stage IV breast cancer...
  49. doi request reprint Prognostic value of body mass index in locally advanced breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1718-25. 2008
    ..The analysis includes the subsets of inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer...
  50. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  51. ncbi request reprint The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1248-54. 2006
    ....
  52. pmc Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Hermann Pressler Drive, Unit 1484, Houston, TX 77030, USA
    Breast Cancer Res 14:R83. 2012
    ....
  53. pmc Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer
    Sao Jiralerspong
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Clin Oncol 27:3297-302. 2009
    ..Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy...
  54. pmc Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy
    Elizabeth A Mittendorf
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:1956-62. 2011
    ..The current study was undertaken to validate this staging system using internal and external cohorts...
  55. ncbi request reprint Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma
    Emer O Hanrahan
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 10, Houston, TX 77030, USA
    J Clin Oncol 25:4952-60. 2007
    ....
  56. doi request reprint Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival
    Garth Beinart
    Department of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:867-74. 2007
    ..The aim of our study was to describe tumor properties, patient characteristics, and method of cancer detection for a large cohort of patients with bilateral breast cancer and to assess the associations of these factors with OS and RFS...
  57. ncbi request reprint Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Jacqueline S Jeruss
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 26:246-52. 2008
    ..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...
  58. doi request reprint Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers
    Catherine M Kelly
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:5161-7. 2010
    ..The authors hypothesized that the test is ordered when clinicopathological variables yield equivocal risk estimates. The current study also showed how often the test clarifies clinically ambiguous risk status...
  59. pmc Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:1202-11. 2012
    ..In the current study, the authors explored the association between metformin use and survival outcomes in patients with triple receptor-negative breast cancer (TNBC) who were receiving adjuvant chemotherapy...
  60. doi request reprint Effect of CYP2D6 polymorphisms on breast cancer recurrence
    Phuong K Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1221-7. 2012
    ....
  61. doi request reprint Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer
    Jeffrey M Albert
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1595-601. 2011
    ..However, some data suggest that patients with ER(+) /PR(-) or ER(-) /PR(+) tumors may have worse outcomes than those with ER(+) /PR(+) tumors. Few data correlate these biomarkers with locoregional (LR) recurrence...
  62. doi request reprint Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy
    Ranjna Sharma
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2899-908. 2010
    ..We sought to determine present-day locoregional recurrence (LRR) rates to better understand the role of postmastectomy radiotherapy (PMRT) in women with 0 to 3 positive lymph nodes...
  63. doi request reprint Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning
    Min Yi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, TX, USA
    Ann Surg 253:572-9. 2011
    ..We utilized 2 different methods and compared sensitivities and specificities between them. Our goal was to determine whether distinguishing NP from TR had prognostic value...
  64. pmc Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Oncologist 18:369-76. 2013
    ..The purpose of this analysis was to compare disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) between pregnant and nonpregnant patients with breast cancer...
  65. ncbi request reprint Development of new cancers in patients with DCIS: the M.D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 15:244-9. 2008
    ..The purpose of this study was to describe clinical characteristics and outcome of mammographically and clinically detected new cancers in patients with previously diagnosed ductal carcinoma in situ (DCIS)...
  66. pmc High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients
    Ashley M Holder
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA
    Breast Cancer Res Treat 137:319-27. 2013
    ..Future studies are needed to define the role of SCD1 in the malignant phenotype of breast cancer and to evaluate the potential for SCD1 as a therapeutic target...
  67. pmc High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients
    Chandra Bartholomeusz
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Oncologist 17:766-74. 2012
    ..66; 95% CI, 0.46-0.95). In conclusion, ERK-2 and pMAPK are valuable prognostic markers in TNBC. Further studies are justified to elucidate ERK's role in TNBC tumorigenicity and metastasis...
  68. ncbi request reprint Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:2113-22. 2006
    ..Node-negative breast cancers that are < or = 1 cm are stage T1a,bN0M0. Controversy surrounds the prognosis of these patients with locoregional therapy only and the need for adjuvant systemic therapy...
  69. ncbi request reprint Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma
    Erika Resetkova
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Cancer 101:913-7. 2004
    ..Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC...
  70. pmc cMET and phospho-cMET protein levels in breast cancers and survival outcomes
    Kanwal P Raghav
    Department of Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2269-77. 2012
    ..To evaluate cMET (mesenchymal-epithelial transition factor gene) and phospho-cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes...
  71. pmc Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome
    Shaheenah Dawood
    Departments of Breast Medical Oncology, Pathology, Quantitative Sciences, Radiotherapy and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas and Department of Medical Oncology, Dubai Hospital, Dubai, UAE
    Breast J . 2010
    ..CXCR4 may represent a novel therapeutic target...
  72. pmc Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
    Kanwal P S Raghav
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:1498-506. 2012
    ....
  73. ncbi request reprint Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:258-63. 2004
    ..The objective of the current study was to determine whether her-2 amplification was associated with a pathologic response to preoperative chemotherapy with taxanes in patients with early-stage breast carcinoma...
  74. ncbi request reprint Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection
    Rosa F Hwang
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Cancer 110:723-30. 2007
    ..The objective of this study was to examine the long-term safety of avoiding CLND in selected patients with positive SLNs...
  75. ncbi request reprint Multifocal breast cancer in women < or =35 years old
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1445-50. 2007
    ..The relation that multifocality at diagnosis had to survival in women < 35 years of age was evaluated...
  76. pmc Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer
    Jing Li
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1675-83. 2011
    ..However, these findings have not been confirmed for inflammatory breast cancer (IBC), which has different biological features than non-IBC...
  77. pmc ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer
    Ruozhen Hu
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Res 71:6524-34. 2011
    ..ZNF668 effectively suppressed breast cancer cell proliferation in vitro and tumorigenicity in vivo. Taken together, our studies identify ZNF668 as a novel breast tumor suppressor gene that functions in regulating p53 stability...
  78. ncbi request reprint Phase II trial of 10-EDAM in the treatment of metastatic breast cancer
    Garth A Beinart
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 60:61-7. 2007
    ..This phase II trial was conducted to assess the efficacy and safety of 10-Ethyl-10-Deaza-Aminopterin (10-EDAM), a folate antagonist, in metastatic breast cancer patients who had received no more than one prior chemotherapy regimen...
  79. doi request reprint Trastuzumab administration associated with change in HER2 status
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 8:366-9. 2008
    ..We present the unusual case of a patient with HER2/neu-positive stage I breast cancer who, after receiving adjuvant trastuzumab, relapsed to develop HER2/neu-negative metastatic disease...
  80. ncbi request reprint Advances in triple receptor-negative breast cancer
    Ana M Gonzalez-Angulo
    Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 5:956-7. 2007
  81. doi request reprint Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4072-7. 2008
    ..To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer...
  82. doi request reprint PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1802-11. 2010
    ..To determine the role of PEA-15 in breast cancer...
  83. ncbi request reprint Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 5:317-9. 2004
    ..A normal male infant was delivered. Upon completion of chemotherapy, the patient underwent mastectomy and axillary lymph node dissection followed by comprehensive radiation therapy to the chest wall...
  84. pmc Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:956-65. 2011
    ..We determined the prognostic value of the expression level of tyrosine 1248-phosphorylated HER-2 (pHER-2) in patients with HER-2(+) primary breast cancer using a reverse-phase protein array...
  85. ncbi request reprint Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
    Wei T Yang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350, Houston, TX, 77030, USA
    Breast Cancer Res Treat 109:417-26. 2008
    ..To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with inflammatory breast cancer (IBC)...
  86. pmc Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1598-604. 2009
    ..Women at a high risk for breast cancer are offered choices for screening or prophylactic surgeries. The aim of this study was to evaluate opinions regarding screening and surgical strategies in high-risk women...
  87. pmc Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer
    Leonel F Hernandez-Aya
    Department of Internal Medicine, University of Miami Miller School of Medicine at FAU, West Palm Beach, Florida, USA
    Oncologist 16:404-14. 2011
    ..Here, we review the biology of the network, its role in the development and progression of breast cancer, and the evaluation of targeted therapies in clinical trials...
  88. pmc Breast cancer diagnosis during pregnancy
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Womens Health (Lond Engl) 5:243-9. 2009
    ..In this article, the use of diagnostic imaging, procedures, surgery and chemotherapy are reviewed as well as prognosis and future pregnancies after the treatment for breast cancer...
  89. doi request reprint Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data
    Selin Carkaci
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Nucl Med 50:231-8. 2009
    ..Our objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory breast cancer (IBC)...
  90. doi request reprint Breast carcinoma with neuroendocrine differentiation and myocardial metastases
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Breast Cancer 7:892-4. 2007
    ..Better understanding of the cellular origin and molecular pathogenesis of this relatively enigmatic rare disease is required...
  91. pmc Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer
    Leonel F Hernandez-Aya
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 29:2628-34. 2011
    ..To evaluate the clinical outcomes and relationship between tumor size, lymph node status, and prognosis in a large cohort of patients with confirmed triple receptor-negative breast cancer (TNBC)...
  92. ncbi request reprint Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast
    Flavia Morales-Vasquez
    Department of Medical Oncology, Instituto Nacional de Cancerologia, Mexico DF, Mexico
    Breast J 13:551-6. 2007
    ..Future studies to identify relevant molecular targets should be implemented in order to define effective therapies for phyllodes tumors of the breast...
  93. ncbi request reprint Inflammatory breast cancer and high-dose chemotherapy: back to the past
    Ana Maria Gonzalez-Angulo
    J Clin Oncol 23:3859-60; author reply 3860-2. 2005
  94. ncbi request reprint Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics
    Bryan T Hennessy
    University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Nat Clin Pract Oncol 2:598-9. 2005
  95. ncbi request reprint Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
    ..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy...
  96. ncbi request reprint Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Breast Cancer 4:415-9. 2004
    ..04). It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer...
  97. ncbi request reprint Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1436-44. 2007
    ..The authors compared the prognostic features of IBC and non-IBC locally advanced breast cancer (LABC) to gain insight into the biology of this disease entity...
  98. ncbi request reprint A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 12:395-402. 2007
    ..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
  99. ncbi request reprint Pharmacodynamic markers of perifosine efficacy
    Bryan T Hennessy
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:7421-31. 2007
    ..Recent studies suggest that perifosine inhibits the phosphatidylinositol-3'-kinase (PI3K) pathway by preventing cell membrane recruitment of the AKT pleckstrin homology domain...
  100. doi request reprint Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
    Deann P Atchley
    Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4282-8. 2008
    ..Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features and clinical features differ in patients with and without BRCA mutations...
  101. ncbi request reprint Overview of resistance to systemic therapy in patients with breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Adv Exp Med Biol 608:1-22. 2007
    ..Table 1 summarizes metastatic breast cancer response rates to single-agent systemic therapy...

Research Grants3

  1. The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
    Ana Gonzalez Angulo; Fiscal Year: 2007
    ..The outcome of this project is expected to position me to submit a competitive R01 application during the fourth year of the proposed award. ..
  2. Funtional Proteomics and Response to Preoperative Theraphy in Breast Cancer
    Ana Gonzalez Angulo; Fiscal Year: 2007
    ....